

Page	1
1 050	_





Abstract

- 26 Background: The emergence of SARS-CoV-2 variants has caused an
- unexpected rebound globally. The World Health Organization has listed three
- variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the
- 29 epidemiology and thereby plan appropriate safety measures, differential
- identification of the variants is indeed critical.
- Objectives: Although whole-genome sequencing is the gold standard for variant
- identification, it is time-consuming and relatively expensive. Therefore, a rapid,
- easy, and cost-effective platform targeting multiple regions of the genome is
- required. Here, we assessed the usefulness of the Novaplex[™] SARS-CoV-2
- Variants I Assay kit in identifying mutations in the variants.
- 36 Study design: We retrospectively examined 30 stored nasal swabs from
- 37 COVID-19-positive patients tested between November 2020 and March 2021.

38 RNA extracted from these swabs was subjected to the commercial kit and 39 real-time reverse transcription-PCR was performed. To determine the genome 40 sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were 4142prepared and mapped to the reference genome. 43 Results: Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored 44 E484K substitution alone. 45 46 Conclusions: The variant with E484K substitution alone ("R.1") has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay 47

was found to be feasible, convenient, and user-friendly in identifying the

51 Keywords: SARS-CoV-2, COVID-19, variant, mutations, whole-genome

sequencing

52

53

54

55

Introduction

Although the global advent of vaccines against severe acute respiratory 56 57 syndrome coronavirus 2 (SARS-CoV-2) has relieved us from the ongoing pandemic, the emergence of SARS-CoV-2 variants has raised new concerns. 58 The World Health Organization (WHO) defines a SARS-CoV-2 variant of interest 59 60 (VOI) as a phenotypically changed isolate that causes community transmission 61 or clusters, and a variant of concern (VOC) as a VOI with increased 62 transmissibility and virulence, or decreased effectiveness of public health and social measures or diagnostics, vaccines, and treatment [1]. As of April 13, 2021, 63

WHO has listed three VOCs: B.1.1.7, B.1.351, and P.1, named the UK variant, 64 65 South Africa variant, and Brazil/Japan variant, respectively, after the places 66 where they were first identified [2]. Among the various mutations emerging in 67 SARS-CoV-2, those in the spike (S) protein, specifically the H69/V70 deletion 68 and E484K N501Y substitution mutations, are important because the S protein is 69 involved in infectivity to host cells via angiotensin-converting enzyme 2 and the main target of neutralizing antibodies induced by vaccines [3]. All three VOCs 70 listed above harbor the N501Y mutation; B.1.1.7 harbors an additional H69/V70 71 72 deletion; and the other two, the E484K substitution mutation. Each mutation alone and in combination determines the phenotypic features of the variants, 73 74such as transmissibility and severity of the coronavirus disease 2019 (COVID-19), and vaccine effectiveness [3,4]. Therefore, prompt differentiation of 75

the SARS-CoV-2 variants is critical to monitor the epidemic situation in the

community and to perform adequate infection control and patient care.

78 Currently, whole genome or complete/partial S-gene sequencing is the 79 gold standard for differentiating SARS-CoV-2 variants [5]. However, genome 80 sequencing requires professional and technical expertise, knowledge of data 81 analysis, and high-end facilities. Additionally, it is time-consuming, laborious, and 82 relatively expensive. Given these circumstances, a rapid, easy, 83 cost-effective platform targeting multiple regions of the SARS-CoV-2 genome is required [6]. NovaplexTM SARS-CoV-2 Variants I Assay is a newly developed 84 multiplex real-time reverse transcription-PCR kit capable of identifying multiple 85 mutations, including the abovementioned ones in a single reaction within 2 hours. 86 87 Here, we report the utility of this commercial kit and discuss its implications in the 88 differential identification of SARS-CoV-2 variants.

Materials and Methods

90

We 91 retrospectively examined the stored nasal swabs from 92 COVID-19-positive patients tested at the Ryukyu University Hospital between 93 November 2020 and March 2021. COVID-19 diagnosis was confirmed by 94 real-time PCR with primer sets developed by the National Institute for Infectious 95 Diseases of Japan [7]. RNA was extracted from the nasal swabs stored in a 96 deep freezer using MagLEAD 12gC (Precision System Science, Chiba, Japan). The extracted RNA was then subjected to the NovaplexTM SARS-CoV-2 Variants 97 I Assay kit (Seegene, Seoul, South Korea) according to the manufacturer's 98 instructions using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, 99 100 Hercules, CA, USA). The test result, either plus or minus, was automatically 101 displayed on the system's monitor with the kit-accompanied software Seegene Viewer V1.0 (Seegene). To determine the genome sequences of SARS-CoV-2 in 102

103 the collected samples, next-generation sequencing libraries were prepared using the multiplex PCR method. Briefly, after reverse transcription using 104 105 SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) and random primers pd(N)₆ (Takara Bio, Shiga, Japan), whole genome 106 107 amplification was conducted using ATRIC Network's modified (V3) primer set [8]. 108 Libraries were prepared using the Nextera XT Library Prep Kit (Illumina, San 109 Diego, CA, USA) and 2 x 151 paired-end sequencing was performed on a MiSeq platform (Illumina, San Diego, CA, USA) with the respective MiSeq v3 Reagent 110 kit. After mapping to the reference genome of SARS-CoV-2 (GenBank accession 111 112 number: NC 045512.2), consensus sequences were obtained using CLC 113 Genomics Workbench ver. 21.0.2 (QIAGEN, Hilden, Germany). This study was 114 approved by the Institutional Review Board of the University of the Ryukyus (approval number: 1621). 115

Results

116

117

126

A total of 30 COVID-19-positive samples were tested. Among them, four 118 samples collected between February and March were determined to be variants; 119 two (cases 1 and 2) were positive for both H69/V70 deletion and N501Y 120 121 substitution mutations (UK variant), while the other two (cases 3 and 4) were 122 positive for E484K substitution mutation alone (Table 1). These results were confirmed by whole-genome sequencing (Figure 1). In terms of usability of the 123 Novaplex[™] SARS-CoV-2 Variants I Assay kit, the procedure was simple and 124 125 easy to perform, and the turnaround time was only 120 minutes (Figure 2).

- Figure 1. Genome sequences of the variants detected in this study.
- Genome sequence data for the four cases are shown. Reference sequences

(Wuhan and Okinawa) and typical mutation patterns are shown in the upper and 129 lower stands, respectively. 130 131 Figure 2. Procedure for real-time reverse transcription-PCR using the 132 commercial Seegene kit and system. 133 PCR mixture was prepared using the extracted RNA and Novaplex[™] 134 SARS-CoV-2 Variants I Assay kit reagents; real-time reverse transcription-PCR 135 was performed using the CFX96 Touch Real-Time PCR Detection System. The 136 test results were automatically displayed on the monitor via the software's 137 138 interface (Seegene Viewer). 139 **Discussion** 140 Many countries are now facing an unexpected rebound of the COVID-19 141

142 pandemic, mainly attributable to the emergence of several SARS-CoV-2 variants. 143 Therefore, prompt identification of the variants is critical for controlling disease 144 spread. Although genome sequencing is considered the gold standard for 145 identifying SARS-CoV-2 variants, it has several limitations in terms of swiftness and convenience. In Japan, as of April 23, 2021, randomly selected 146 147 COVID-19-positive samples were tested for the N501Y mutation at local public health institutes and affiliated hospitals, and the positive samples along with a 148 few negative ones were sent to a central public health institute (National Institute 149 of Infectious Diseases, Tokyo, Japan) for whole-genome sequencing [9]. 150 Although dependent upon several factors, such as the local situation of the 151 152 COVID-19 epidemic and geographical conditions, it usually takes a week to receive the final report of genome sequencing. This limitation can be overcome 153 by the NovaplexTM SARS-CoV-2 Variants I Assay kit that can substantially 154

shorten the turnaround time.

155

156 Since many variants are emerging, there is a possibility that 157 monoplex-based testing can miss detecting some of the characteristic mutations in the variants. We detected two samples with the E484K mutation and without 158 the N501Y mutation in this study. This variant has been named R.1 and 159 160 categorized as a VOI in Japan as of April 7, 2021; however, this variant could bypass the screening stage in our country. Therefore, we need a 161 multiplex-based test that can examine several mutations simultaneously. 162 In conclusion, the Novaplex[™] SARS-CoV-2 Variants I Assay is a simple, 163 164 rapid, and easy to perform method, and can identify three important mutations simultaneously. An additional advantage of this commercial kit is that it can be 165 used with conventional real-time thermal cyclers. We believe that the 166 widespread application of this kit can help in the convenient identification of the 167

168	viral variants.
169	
170	Declaration of competing interest
171	The authors have no conflicts to declare.
172	
173	Acknowledgements
174	We would like to thank Editage (<u>www.editage.com</u>) for English language editing.
175	We also thank Dr. Kentaro Tanaka for his technical support in performing
176	genome analysis.
177	
178	Funding
179	None.
180	

D	~4	_		_		_
Г	еı	е	е	n	ces	5

- 182 [1] World Health Organization, COVID-19 weekly epidemiological update.
- Special edition: Proposed working definitions of SARS-CoV-2 variants of interest
- and variants of concern, 2021.
- https://www.who.int/docs/default-source/coronaviruse/situation-reports/2021022
- 186 <u>5_weekly_epi_update_voc-special-edition.pdf?sfvrsn=1eacfa47_7&download=tr</u>
- 187 <u>ue</u>.
- 188 [2] World Health Organization, Weekly epidemiological update on
- 189 COVID-19, 2021.
- 190 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covi
- 191 <u>d-19---13-april-2021</u>.
- 192 [3] C.E. Gómez, B. Perdiguero, M. Esteban, Emerging SARS-CoV-2
- 193 variants and impact in global vaccination programs against

194	SARS-CoV-2/COVID-19, Vaccines 9 (2021) 243. doi:
195	https://doi.org/10.3390/vaccines9030243.
196	[4] G. Nelson, O. Buzko, P. Spilman, K. Niazi, S. Rabizadeh, P.
197	Soon-Shiong, Molecular dynamics simulation reveals E484K mutation enhances
198	spike RBD-ACE2 affinity and the combination of E484K K417n and N501y
199	mutations (501Y.V2 variant) induces conformational change greater than N501Y
200	mutant alone, potentially resulting in an escape mutant, bioRxiv 2021. doi:
201	https://doi.org/10.1101/2021.01.13.426558.
202	[5] European Centre for Disease Prevention and Control, and World Health
203	Organization Reginal Office for Europe, Methods for the detection and
204	identification of SARS-CoV-2 variants, 2021.
205	https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detec

tion-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf.

- 207 [6] World Health Organization, Genomic sequencing of SARS-CoV-2: A
- 208 guide to implementation for maximum impact on public health, 2021.
- https://apps.who.int/iris/handle/10665/338480.
- [7] K. Shirato, N. Nao, H. Katano, I. Takayama, S. Saito, F. Kato, et al,
- 211 Development of genetic diagnostic methods for detection for novel coronavirus
- 212 2019 (nCoV-2019) in Japan, Jpn. J. Infect. Dis. 73(4) (2020) 304–307. doi:
- 213 <u>10.7883/yoken.JJID.2020.061</u>.
- 214 [8] K. Itokawa, T. Sekizuka, M. Hashino, R. Tanaka, M. Kuroda,
- 215 Disentangling primer interactions improves SARS-CoV-2 genome sequencing
- by multiplex tiling PCR, PLOS ONE 15(9) (2020) e0239403. doi:
- 217 <u>10.1371/journal.pone.0239403</u>.
- 218 [9] T. Takenouchi, Y.W. Iwasaki, S. Harada, H. Ishizu, Y. Uwamino, S. Uno,
- et al, Clinical utility of SARS-CoV-2 whole genome sequencing in deciphering

220 source of infection, J. Hosp. Infect. 107 (2021) 40-44. doi:

https://doi.org/10.1016/j.jhin.2020.10.014.

	RdRP	Ct	H69/V70 del	Ct	E484K	Ct	N501Y	Ct
Case 1	(+)	24.23	(+)	27.43	(-)	0.00	(+)	28.08
Case 2	(+)	38.27	(+)	37.08	(-)	0.00	(+)	37.86
Case 3	(+)	31.85	(-)	0.00	(+)	33.11	(-)	0.00
Case 4	(+)	20.22	(-)	0.00	(+)	21.25	(-)	0.00

Table 1. Result of PCR performed using the NovaplexTM SARS-CoV-2 Variants I Assay kit.


223

224

The RdRP gene was included in this assay to confirm the presence of SARS-CoV-2. Endogenous internal controls of all

samples were positive. (+) and (-) represent positive and negative, respectively. Abbreviations: del, deletion; Ct, cycle


Figure 1



(2 hours)

Figure 2

(10 minutes)



(110 minutes)